1 / 20

Transforming Health Care Through Personalized Medicine

Transforming Health Care Through Personalized Medicine. Catherine A. McCarty, PhD, MPH Senior Research Scientist Interim Director, Center for Human Genetics. Personalized Medicine Research Project. Ultimate Goal:

caia
Download Presentation

Transforming Health Care Through Personalized Medicine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transforming Health Care Through Personalized Medicine Catherine A. McCarty, PhD, MPH Senior Research Scientist Interim Director, Center for Human Genetics

  2. Personalized Medicine Research Project • Ultimate Goal: • Translate genetic data into specific knowledge about disease that is clinically relevant and will enhance patient care • Short term Goal: • Establish database to allow research in genetic epidemiology, pharmacogenetics, population genetics

  3. Personalized Medicine Research Project • Phase I: Consultation and initial enrollment, completed April 2004 • Phase II: Creating the infrastructure for a national resource and expanding the database • Phase III: Genetic discovery projects, community and physician education and consultation

  4. Consultation • Community Advisory Group • Scientific Advisory Board • Ethics and Security Advisory Board • Focus group discussions • Community talks • Media releases

  5. Marshfield Epidemiologic Study Area (MESA) Well studied population Primarily Marshfield Clinic patients Many families have lived in MESA for many generations Why Marshfield?

  6. Why Marshfield? • Marshfield Clinic system of care • Extensive Electronic Medical Record for two decades • MECCA disease lexicon • Electronic prescription data • Research Foundation with strong programs in genomics and clinical research • Security Health Plan to capture diagnoses outside the Marshfield Clinic • 55% overall

  7. Study Logistics • MESA residents aged 18+ contacted by letter and telephone (600-1000 letters per week) • 30-90 participants per day (30 minute appts) • Written informed consent and questionnaire • Allows sharing of samples and data • Consenting participants donate blood for DNA extraction, storage of plasma and serum • $20 reimbursement for expenses (10% return) • Dietary history questionnaire and Baecke physical activity questionnaire ($10)

  8. Participant/Non-Participant Comparison19,723 enrolled 6-1-08

  9. Race Caucasian, 98.2% American Indian, 0.9% Hispanic, 1.1% Asian, 0.5% Other, 0.3% African American, 0.3% Ethnicity German, 76.2% Irish, 17.3% English, 16.6% Other, 16.6% Polish, 12.6% Norwegian, 11.9% French, 9.8% Swedish, 6.8% Dutch, 6.4% Czech, 3.8% Participant Demographics

  10. Participant Residence • Current • Working farm, 7.9% • Rural home or hobby farm, 30.2% • Suburb, city, village, 61.8% • Other, 0.1% • Ever lived on a working farm, 51.7%

  11. Participant Exposure Status • Smoking status: • Current, 19.1% (22% in Wisconsin, 2003) • Past, 27.0% • Never, 53.4% • Personal and/or family history of adverse drug reactions, 14% • 55.3% rash • 22.3% swelling • 19.3% breathing problems • 15.7% hospitalized (n=427)

  12. Opt-out on Consent form • 168/19,692 (0.9%) participants ask to not be contacted for future studies • 65% agreed to complete dietary and physical activity questionnaires when asked

  13. Distribution of Years of Health Information Available Majority has 20+ years of health data

  14. Process to Access Samples • Feasibility request for phenotype • Scientific merit review • External peer-reviewed funding mechanism OR Marshfield Clinic Research Committee • IRB review/approval for all studies • Oversight Committee to release samples • Funding is required for phenotyping and identification and retrieval of samples • Data deposit within 6 months after completing analyses

  15. Pharmacogenetics Projects • Statin efficacy and adverse reactions • Warfarin (blood thinner) • Topical beta-blockers for glaucoma • Metformin for diabetes • Tamoxifen in breast cancer

  16. Genetic Epidemiology Projects • Alzheimer’s Disease • Multiple sclerosis • Vertebral malformations • Fibromyalgia syndrome • Osteoporosis • Cataract and low HDL • Hypertensive heart disease • Glaucoma • Myocardial infarction • Coronary artery disease • Dyslipidemia in severely obese subjects

  17. Other Activities • Molecular finger printing and master plating of DNA samples • Quality control for serum and plasma samples • Twice-yearly newsletter to subjects

  18. Infrastructure Funding • Office of Rural Health Policy, Health Resources and Services Administration 1 D1A RH00025-01 • Technology Development Fund Program, Department of Commerce, State of Wisconsin • Marshfield Clinic • Approximately $150 per person to enroll in Phase 1 • Currently $250 per person to enroll with smaller staff

  19. Summary • Population-based biobank with nearly 20,000 adults enrolled • DNA, plasma and serum samples • Diet and activity questionnaires • Access to electronic medical records • Ability to recontact subjects • Consent to share data and samples

  20. www.mfldclin.edu/pmrp

More Related